Pancreatic Cancer Research

ResearcherUniversity of CopenhagenActive in the last 2 years

Inna Markovna Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2891-0762; OpenAlex author ID A5071985590. Sources: ClinicalTrials.gov.

Their work

Papers
43 (first author 4, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
89
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 3 papers, 1 trial · 2021: 7 papers · 2022: 7 papers · 2023: 10 papers · 2024: 1 paper · 2025: 10 papers · 2026: 2 papers

Papers 43

  1. Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates. Co-author DOI 10.1038/s41392-026-02626-3↗
  2. Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/life16091499↗
  3. Symptom burden and quality of life in patients with pancreatic and peri-pancreatic cancer at admission to specialized palliative care: a nationwide register-ba… First author DOI 10.1007/s00520-025-10212-6↗
  4. A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). Co-author DOI 10.1016/j.iotech.2025.101054↗
  5. BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target. Co-author DOI 10.1038/s41598-025-24463-0↗
  6. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Co-author DOI 10.1126/sciadv.ads5002↗
  7. The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. Co-author DOI 10.1158/1078-0432.ccr-25-0758↗
  8. Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ducta… Co-author DOI 10.1186/s12885-025-14283-w↗
  9. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… Co-author DOI 10.1200/jco-25-01631↗
  10. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… Co-author DOI 10.1200/jco.23.01965↗
  11. Paired Comparison of Whole Genome Sequencing and Comprehensive Targeted Sequencing of Pancreatic Cancer Tissue. Co-author DOI 10.21873/anticanres.17447↗
  12. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  13. Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art … Co-author DOI 10.7759/cureus.68386↗
  14. Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Co-author DOI 10.1002/cam4.5240↗
  15. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  16. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Co-author DOI 10.1016/j.ejca.2022.11.035↗
  17. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. Co-author DOI 10.1136/jitc-2022-006432↗
  18. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
  19. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
  20. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherap… Last author DOI 10.3389/fimmu.2023.1228907↗
  21. High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fmolb.2023.1158058↗
  22. Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15030897↗
  23. Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records. Co-author DOI 10.7554/elife.84919↗
  24. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  25. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (Che… Co-author DOI 10.1200/jco.21.02511↗
  26. Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibro… Co-author DOI 10.3390/biom12091315↗
  27. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030819↗
  28. Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Co-author DOI 10.3390/cancers14133250↗
  29. Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Co-author DOI 10.3390/cells11233763↗
  30. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic C… Last author DOI 10.3390/pharmaceutics14030509↗
  31. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenoc… Co-author DOI 10.1002/ijc.33551↗
  32. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ejca.2020.10.038↗
  33. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival i… Co-author DOI 10.1016/j.ejca.2021.09.009↗
  34. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  35. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Co-author DOI 10.1158/1078-0432.ccr-20-4215↗
  36. Regional and age differences in specialised palliative care for patients with pancreatic cancer. First author DOI 10.1186/s12904-021-00870-8↗
  37. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. First author DOI 10.3390/cancers13184599↗
  38. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.32751↗
  39. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. First author DOI 10.1111/ecc.13219↗
  40. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0672↗
  41. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  42. Checkpoint inhibitors in pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2019.06.005↗
  43. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenoca… Co-author DOI 10.18632/oncotarget.22080↗

Trials 1

  1. Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer Principal investigator NCT04258150↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia Sidenius Johansen · 33 shared papers, 2017–2025 · strength 5.13
  2. Carsten Palnæs Hansen · 16 shared papers, 2020–2026 · strength 2.40
  3. Astrid Zedlitz Johansen · 15 shared papers, 2020–2025 · strength 2.07
  4. Dorte Lisbet Nielsen · 12 shared papers, 2019–2025 · strength 2.04
  5. Susann Theile · 9 shared papers, 2022–2026 · strength 1.78
  6. Louise S. Rasmussen · 10 shared papers, 2020–2025 · strength 1.43
  7. M.A. Karsdal · 8 shared papers, 2020–2025 · strength 1.25
  8. Nicholas Willumsen · 8 shared papers, 2020–2025 · strength 1.25
  9. Per Pfeiffer · 9 shared papers, 2020–2025 · strength 1.15
  10. Lars Nannestad Jørgensen · 6 shared papers, 2021–2025 · strength 0.98
  11. Hadi M. H. Diab · 6 shared papers, 2021–2025 · strength 0.98
  12. Neel Ingemann Nissen · 6 shared papers, 2021–2025 · strength 0.92
  13. Estrid Vilma Solyom Høgdall · 3 shared papers, 2023–2025 · strength 0.73
  14. Rasmus S. Pedersen · 4 shared papers, 2022–2025 · strength 0.72
  15. Morten Bækbo Ladekarl · 4 shared papers, 2022–2025 · strength 0.69
  16. Sidsel C. Lindgaard · 4 shared papers, 2021–2025 · strength 0.68
  17. Lars Henrik Jensen · 3 shared papers, 2023–2025 · strength 0.60
  18. Jessica Xin Hjaltelin · 3 shared papers, 2022–2023 · strength 0.49
  19. Søren Brunak · 3 shared papers, 2022–2023 · strength 0.49
  20. Mathilde Adsersen · 2 shared papers, 2021–2025 · strength 0.48
  21. Rasmus Erik Johansson Mortensen · 2 shared papers, 2023–2026 · strength 0.47
  22. Mads Hald Andersen · 2 shared papers, 2023–2026 · strength 0.47
  23. Claus Wilki Fristrup · 2 shared papers, 2022–2025 · strength 0.47
  24. Britta Weber · 3 shared papers, 2022–2023 · strength 0.46
  25. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.